Advertisement

Picture EBD Group BioPharm America 2018 Boston September 600x60px
Document › Details

Synthelis. (2/27/18). "Press Release: Synthelis and BioMeca Sign a Commercial Agreement to Promote a Joint Service Offering". Lyon.

Organisations Organisation Synthelis (FR)
  Organisation 2 BioMeca (FR)
Products Product protein expression technology
  Product 2 Atomic Force Microscopy (AFM)
Index term Index term BioMeca–Synthelis: proteomic services, 201802– collab joint services for production + folding validation of difficult-to-express proteins
Persons Person Chlasta, Julien (BioMeca 201802 President + Co-Founder)
  Person 2 Tillier, Bruno (Synthelis 201101– President + Co-Founder)
     


As of February 12, 2018, Synthelis and BioMeca combine their know-how and thus capitalize on their respective technology in developing a joint offer, responding to the needs of their customers.

This joint offering is based on the production of difficult-to-express proteins and the validation of their proper folding by Atomic Force Microscopy (AFM). Thus, this offer combines the cutting-edge expertise of two recognized players in their respective domain: Synthelis, for its cell-free patented technology and BioMeca, for its expertise in the field of mechanical measurement on biological materials.

"We are very happy with this partnership that answers a real need in the quality control market of transmembrane proteins. We hope to provide a total satisfaction to our customers in making our best efforts to meet their specific requirements. This partnership fully complies with our development strategy, which is to characterize the nano-structure of proteins" says Julien Chlasta, President, cofounder of BioMeca.

Bruno Tillier, President of Synthelis says: "This agreement with BioMeca greatly answers the expectations of our customers in providing them with an accurate quality control on our protein and proteoliposome samples. Thanks to the AFM expertise of BioMeca, we can now confirm the proper folding of the protein we produce by determination of the number of transmembrane domains. For our proteoliposome format, the orientation and the number of proteins by liposome can also be determined by our partner. We are thus delighted of the added value of this agreement both for our clients as well as for our respective business ».


For more information:

BioMeca
46 Allée d’Italie
69007 Lyon - France
Tel: + 33 (0) 4 72 72 89 35
contact@bio-meca.com

Synthelis
BIOPOLIS
5, avenue of the Grand Sablon
38700 La Tronche - France
Tel: + 33 (0) 4 76 54 95 35
contact@synthelis.fr


About BioMeca:

Founded in 2016, BioMeca is a company specializing in the analysis of biological material by atomic force microscopy (AFM). BioMeca has developed several analytical solutions to optimize culture conditions of different samples (like cells, tissues...). In this context, BioMeca has developed several innovative analytical methods for nano-structural characterization of materials and the study of biological samples.

More information on www.bio-meca.com


About Synthelis:

Founded in 2011, Synthelis is a service provider in the field of production, purification, formulation, and characterization of proteins. In this context, Synthelis has developed a patented process to produce functional membrane proteins stabilized in artificial liposomes forming proteoliposomes. Synthelis’team has thus acquired a specific know-how to express any kind of recombinant protein with a cell-free expression system mainly based on bacterial lysates.

More information on www.synthelis.com

   
Record changed: 2018-03-27

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 600x80px

More documents for Synthelis (FR)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2018 Boston September 600x60px




» top